Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan - Test2 - elhamkhani - TriplyDB

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

http://www.wikidata.org/entity/Q24328949

about

Immune response and immunopathology during toxoplasmosis Targeting the indoleamine 2,3-dioxygenase pathway in cancer The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and Autoimmunity The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts The role of IDO in brain tumor immunotherapy IDO2 in Immunomodulation and Autoimmune Disease Trial watch: IDO inhibitors in cancer therapy Indoleamine 2,3 dioxygenase in intestinal disease Molecular evolution and characterization of fungal indoleamine 2,3-dioxygenases.IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity Targeted immune therapy of ovarian cancer Research progress of indoleamine 2,3-dioxygenase inhibitors Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes.HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects.Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary to Type 2 Diabetes: Relationship to Inflammatory Markers.The role of placental tryptophan catabolism Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression Towards a genetic definition of cancer-associated inflammation: role of the IDO pathway Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO).Immune tolerance induction by integrating innate and adaptive immune regulators.Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface.Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis.IDO is a nodal pathogenic driver of lung cancer and metastasis development.Indoleamine 2,3 dioxygenase and metabolic control of immune responses.Tryptophan-catabolizing enzymes - party of three IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan.Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation.IDO2 is a critical mediator of autoantibody production and inflammatory pathogenesis in a mouse model of autoimmune arthritis.Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase.The cross-talk between opportunistic fungi and the mammalian host via microbiota's metabolism.O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance

P2860

04c8406f00fc63fe5217a1477418b130a5441dd0 0a0969eeb1be45ef3d6b8b52915b9dbc71c28bce 1e024ddae92b2fa3f56e997c4477f8471d10b5fa 6369852c31fcfb0655f2b6039c6dc0ab1367334a 698edb13f513a98ee694311e300d24a2f2b3a49a 8203b0cb9c456f56793eee7df88445c02110327c 8969b7078d2e1fc4812dc01650b6cb177ea04394 a5e0597c10ec49938b2342faf5f7faaf17d83661 bc89931c97719dcc9f90448ea3bbfc96b2b94462 c421dcda07b0c5d90471e7d4334b9202b605b933

P248

Q24612341-AD5FD67B-772F-46B9-AD24-5D04DE3EC11C Q26775471-1F973FAD-8B6E-45AC-9585-4B52D581140D Q26785900-568CD622-C657-4D83-A611-0BD8A62D7DCE Q26822976-DC680EB1-79C1-4362-A81C-879C2CDE856F Q26825202-A2CEF0A5-12B2-4328-B87A-9D5C397F9796 Q26830399-ED231151-2B61-4693-8763-FD1962F4DD64 Q27006786-C47FDC03-7E1F-4A51-8DE7-0FFEFE9D69E0 Q27006866-0374BD4F-BACC-4DCE-9853-7D4D776F7617 Q27025063-66A82B1D-5BFC-45B4-8813-5EC8C58E4E9B Q27932755-94FA64B8-BB13-475B-91B7-069663D49D9B Q28069295-68074DC9-61C3-489D-9E07-A64D4EB9AB7A Q28082828-B92434A0-3868-419D-AD23-32AED7AAFBEB Q28257093-A78344B7-CFE3-4B31-ABFF-382AB0B8FB61 Q28508390-FEB311AB-47B3-4574-8293-7E8271920184 Q28547142-A4BA1592-55C8-4775-B703-95D2FBAE5C03 Q28588016-0ABE4873-07B0-4CA3-B2FC-288B216F69D4 Q28744405-E0F76142-7C7E-4C3E-84CD-CE3F3B784B37 Q30931726-C4C23382-FE72-4276-A718-911F1B046E85 Q33359564-0E5ABC8C-9951-4CD2-A307-7B2B4EDCE94B Q33583816-258CE66A-1411-4C0A-AAFB-3A5D3F6B65FA Q33585122-C8424759-2BB0-4FD8-819A-62C34B811643 Q33657987-FF499695-BEC0-4EAB-AC8C-B441A8E43E77 Q33783132-BF115947-4403-422A-8B70-B2FFE6C0EE80 Q33816244-2ECC8CFB-1A43-4C5C-960B-9016FD5D18D7 Q33832055-4A83E9F5-C81F-4A2D-9E4F-9CD8416355CF Q33907609-651A93D5-D8FD-404F-979C-E355B506575D Q33960301-1F68D515-750C-41FB-9772-2A203B0F4367 Q34154099-7F39CB59-DB36-4526-A7A3-3EB82A1D8515 Q34289698-E361F1CE-96D6-48E0-B84A-4CD99D929634 Q34308495-85B73CEC-3685-4D79-B355-3850A5ACF2D5 Q34313731-020D85BB-B3A9-45FA-A3CA-62D6A915F18D Q34319398-910D661A-A44B-4697-8499-2120FAB31031 Q34393455-84A8327A-9421-4021-BF68-78D01562FA5B Q34396547-BD8C751D-5C96-402F-8BE3-CC814AF8BBF4 Q34401702-09530799-187E-43AF-903F-67AA7DDBF366 Q34414152-67C17DE6-F3A3-4296-8137-668D30ED3CCB Q34427452-7FD255BE-65E3-4DA9-8312-EAAB7C88F1D7 Q34448291-313E2B14-3C1F-48FB-B749-2676C073ADA5 Q34506977-BF90BB7B-D808-4B94-818F-4A8623337C91 Q34512092-3358A3BB-E5D9-4236-83C5-A3D576B7D0FB

P2860

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

http://www.wikidata.org/entity/Q24328949

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@ast

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en-gb

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@nl

type

label

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@ast

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en-gb

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@nl

prefLabel

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@ast

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en-gb

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@nl

P1433

Q24328949-A013FAF3-BE21-4014-A7A7-E533C8D9D7CB

P1476

Q24328949-6F74E417-5F51-4675-927C-D10DB59BDF13

P2093

Q24328949-05600FEC-1D9F-4334-A21C-99F089A5B784

Q24328949-1D380869-3AE5-4046-AF2F-53BEE3B4A61D

Q24328949-2BE982C1-3B71-4F58-9350-82D22F189F03

Q24328949-5BA566BD-5D67-4E5D-8381-BD19FB5EB062

Q24328949-62C765FD-4333-4BFF-93D3-AD265389A8FF

Q24328949-89C1046E-D539-4716-A364-696FF9A96137

P304

Q24328949-2AA0601F-3A4E-4E1D-BF31-1E5DB4E1BCBB

P31

Q24328949-79E3526E-E494-4D32-ADF7-AC205B504CF1

P3181

Q24328949-68A74BCF-E970-48C4-8B12-B4C2010EEEE0

P356

Q24328949-92453DDB-5A08-4CCF-9EF5-1970AA8F374D

P407

Q24328949-807478D1-D883-47E9-B213-13E0A6D8E02F

P433

Q24328949-DF198FEF-2075-4776-8D8B-856D508C55A8

P478

Q24328949-C59E3A02-6178-412D-96B9-5CB33DB31F7E

P577

Q24328949-A26A392C-EA3F-4F36-84F1-2A27EFF95CBE

P5875

Q24328949-5CB78FAE-AEE3-43AB-8895-74F01B948444

P698

Q24328949-63746BA4-0483-44DA-944F-2499CBF7EA12

P921

Q24328949-31397A49-868A-4B80-8450-74DB8F0D1A19

Q24328949-70D8CA6E-ECE9-4F29-9573-CDC3E0D2E780

Q24328949-C1BFF413-7FE7-437F-A69C-5C08711C9A3B

Q24328949-CAA6E8C5-BA55-471F-98B4-DF80F4299A75

Q24328949-ED79033F-58FA-4DFB-AA4A-E6FA30ADAE66

P3181

P356

0008-5472.CAN-07-1872

P1433

Cancer Research

P1476

Novel tryptophan catabolic enz ...... compound D-1-methyl-tryptophan

@en

P2093

Alexander J Muller

http://www.w3.org/2001/XMLSchema#string

George C Prendergast

http://www.w3.org/2001/XMLSchema#string

James B Duhadaway

http://www.w3.org/2001/XMLSchema#string

Lisa Laury-Kleintop

http://www.w3.org/2001/XMLSchema#string

Richard Metz

http://www.w3.org/2001/XMLSchema#string

Uma Kamasani

http://www.w3.org/2001/XMLSchema#string

P304

7082-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4911117

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-07-1872

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6168497

http://www.w3.org/2001/XMLSchema#string

P698

17671174

http://www.w3.org/2001/XMLSchema#string

P921

indoleamine 2,3-dioxygenase activity

Indoleamine 2,3-dioxygenase 1

Indoleamine 2,3-dioxygenase 2

Indoleamine 2,3-dioxygenase 2